)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aytu Biopharma
Aytu Biopharma (AYTU) investor relations material
Aytu Biopharma Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary27 Oct, 2026
Executive summary
Annual meeting scheduled for Dec. 10, 2026, at 10:00 a.m. Mountain time, in person in Denver; voting deadline is Dec. 9, 2026, at 11:59 p.m. Eastern time.
Board recommends voting for all five listed proposals, including director nominees, equity plans, auditor ratification, and the advisory executive compensation vote.
Voting matters and shareholder proposals
Director nominees: Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav “Abi” Jain, and Vivian H. Liu; Board recommends for each.
Board recommends approval of Amendment No. 2 to the 2023 Equity Incentive Plan, adding 500,000 reserved shares and bringing the total to 1,000,000, excluding certain prior-plan and returned shares.
Board recommends approval of the 2027 Employee Stock Purchase Plan.
Board recommends ratifying Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending June 30, 2027.
Board recommends approval of the advisory vote on executive compensation.
Board of directors and corporate governance
Five director nominees are up for election: Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav “Abi” Jain, and Vivian H. Liu.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aytu Biopharma
- Five shareholder votes include expanded equity programs and a new ESPP planned for 2027.AYTU
Proxy filing - EXXUA's launch drives growth prospects, with strong market uptake and a robust financial outlook.AYTULytham Partners Fall 2026 Investor Conference
- EXXUA launch drives growth in CNS therapeutics, with FY26 revenue at $66.4M.AYTUCorporate presentation
- Q4 revenue rose 6.4% to $16.1M, driven by EXXUA's launch and strong prescription growth.AYTUQ4 2026
- EXXUA's unique profile and RxConnect network drive strong early growth and market resilience.AYTUPlanet MicroCap Las Vegas 2026
- EXXUA’s launch and unique profile are fueling growth and strengthening CNS market leadership.AYTUCorporate presentation
- EXXUA launch drives revenue growth and positions the CNS portfolio for further expansion.AYTUCorporate presentation
- EXXUA’s launch drives growth as legacy ADHD revenues decline, with strong financial footing.AYTULytham Partners Spring 2026 Investor Conference
- Exxua’s launch targets rapid growth in the depression market, leveraging unique access and sales strategies.AYTU2nd Annual Lytham Partners Healthcare Investor Summit
Next Aytu Biopharma earnings date
Q1 202712 Nov, 2026
Aytu Biopharma
Next Aytu Biopharma earnings date
Q1 202712 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aytu Biopharma Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare and pediatric-onset disorders. The company’s portfolio includes prescription therapeutics and consumer health products targeting genetic, neurological, and respiratory conditions. It operates through research, licensing, and marketing of branded pharmaceuticals. Aytu Biopharma Inc is headquartered in Englewood, Colorado, and its shares are listed on the NASDAQ.